· Published by Health Canada · Official notice
This is duplicated text of a letter from Sanofi Pasteur Limited. Contact the company for a copy of any references, attachments or enclosures.
October 1, 2012
Dear Health Care Professional
Subject: Voluntary Recall of Sanofi Pasteur Vi polysaccharide typhoid vaccine, TYPHIM Vi® batches with potentially lower than expected antigen content
Sanofi Pasteur, in consultation with Health Canada, would like to inform you of the decision to voluntarily recall several Salmonella typhi Vi Capsular Polysaccharide Vaccine (TYPHIM Vi®) batches with potentially lower than expected antigen content. The results of recent investigations suggest variability in the content of the active component (polysaccharide) in some syringes and 20-dose vials of the following batches that are being recalled: G1122-1, G1557-1, G0182-2, H0176-1.
TYPHIM Vi® is indicated for active immunization against S. typhi, the organism which causes typhoid fever, in persons 2 years of age or older.
Vaccination against typhoid fever does not preclude the recommendation to avoid exposure to potentially contaminated food and drink and all hygienic recommendations must be carefully maintained.
Although Sanofi Pasteur does not have clinical trial data on the immunogenicity and efficacy of TYPHIM Vi® with antigen content below specification, Sanofi Pasteur does not recommend revaccination earlier than otherwise indicated.
Currently there is no available commercial kit to easily evaluate the level of anti-Vi serum antibodies of individuals and, furthermore, there is no validated immunological Vi antibody-based surrogate of protection for typhoid fever.
In Canada, there are 2 other suppliers of alternative typhoid vaccines. There are no published efficacy or immunogenicity data of an oral attenuated S.typhi vaccine in subjects initially vaccinated with a Vi polysaccharide vaccine.
Actions to be taken:
In all cases, Sanofi Pasteur recommends that the decision to vaccinate and re-vaccinate an individual is taken when the benefit of vaccination outweighs the risk of non-vaccination according to the level of exposure to typhoid fever.
Managing marketed health product-related adverse events depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse events are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse events for vaccines in patients receiving TYPHIM Vi® should be reported to Sanofi Pasteur Limited or the Public Health Agency of Canada at the following addresses:
Sanofi Pasteur Limited
Pharmacovigilance Department
1755 Steeles Avenue West, Toronto, Ontario, Canada M2R 3T4
Tel: 1-888-621-1146 or Fax: 416-667-2435
To correct your mailing address or fax number, contact Sanofi Pasteur Limited.
How to report a suspected Adverse Event following Immunization:
If a patient experiences an adverse event following immunization, please complete the Adverse Events Following Immunization (AEFI) Form and send it to the local health department in your province or territory.
The Adverse Events Following Immunization Reporting Form and Guidelines can be found on the Public Health Agency of Canada Web site or in the Canadian Compendium of Pharmaceuticals and Specialties.
If you have any questions or have difficulties contacting your local health department, please contact the Vaccine Safety Section at the Public Health Agency of Canada at:
Telephone: 613-954-5590, 1-866-844-0018
Fax: 613-954-9874; 1-866-844-5931
original signed by
Antigona Tomovici, MD
Director, Medical Affairs